Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report

RATIONALE: Lung cancer is a leading cause of cancer-related mortality worldwide. Currently, targeted therapy has proved highly efficient in the treatment of advanced non-small cell lung cancer (NSCLC). Mesenchymal-epithelial transition factor (MET) is considered a validated molecular target in NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Ruo-Yan, Liu, Ling-Shuang, Zhang, Hui-Yong, Lu, Cheng-Hua, Guo, Xiao-Yan, Zhang, Ling-Yue, Yuan, Xin-Bei, Xue, Hong-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850643/
https://www.ncbi.nlm.nih.gov/pubmed/33530219
http://dx.doi.org/10.1097/MD.0000000000024300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850643/
https://www.ncbi.nlm.nih.gov/pubmed/33530219
http://dx.doi.org/10.1097/MD.0000000000024300

Ejemplares similares